Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study - Wikidata - wikimedia - TriplyDB

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

http://www.wikidata.org/entity/Q30413713

about

Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients Modern brain tumor imaging Nuclear Overhauser Enhancement imaging of glioblastoma at 7 Tesla: region specific correlation with apparent diffusion coefficient and histology The basics of diffusion and perfusion imaging in brain tumors MR Imaging Biomarkers in Oncology Clinical Trials Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis Opportunities and challenges for successful use of bevacizumab in pediatrics.Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients Imaging biomarkers for antiangiogenic therapy in malignant gliomas.Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics.Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.Diffusion tensor histogram analysis of pediatric diffuse intrinsic pontine glioma Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan.Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot study Advances in neuro-oncology imaging.Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma Mean apparent diffusion coefficient values in defining radiotherapy planning target volumes in glioblastoma.Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials.Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques.Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium.Multi-site Study of Diffusion Metric Variability: Characterizing the Effects of Site, Vendor, Field Strength, and Echo Time using the Histogram Distance Emerging biomarkers in glioblastoma Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.Investigation of the diffusion abnormality index as a new imaging biomarker for early assessment of brain tumor response to radiation therapy.Repeatability of derived parameters from histograms following non-Gaussian diffusion modelling of diffusion-weighted imaging in a paediatric oncological cohort.Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma.Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome.Assessing and monitoring intratumor heterogeneity in glioblastoma: how far has multimodal imaging come?Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.Quantitative Imaging Biomarkers for Risk Stratification of Patients with Recurrent Glioblastoma Treated with Bevacizumab.The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma.Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation.

P2860

Q26796223-76E6284E-E984-4415-A553-3831896680D4 Q26853308-3E449430-EE71-4430-AC92-6291B3DEE5F3 Q27002344-F2946A03-A1C6-40DF-9ECF-959868EE580A Q28544667-88D608C3-4E00-4749-BFFA-1FB171FA9924 Q28606582-362A4A35-D651-4A7D-99D8-8A7BEEB1E4CA Q30364608-32689992-B304-4FD3-A188-C1A5DFF8B662 Q30393183-A2073ABE-6D77-4378-8F88-09BC533AC597 Q30454883-0CE92943-2B81-44A1-AD27-1AFF29E5AA0B Q30692995-57782555-CCAE-4985-B1F7-6F5751C0031C Q30764736-C5DD3CD5-5702-4642-901D-F793A12218B8 Q30870628-035CF4E0-7C3B-4700-ABDB-B9A967002EEE Q30907831-01E26533-9247-4DD6-874A-7BE594501874 Q31113520-D8A17544-7EE3-49E3-A0FF-E740D1A9552F Q33616649-E91E3902-06A2-4097-9F9F-A8854C11C188 Q33810394-27EE7E6A-6616-49C9-AA23-B585E5E7D184 Q35028897-CBCA5406-8C35-46AB-A6B8-A343BB5941A2 Q35133246-A77453AA-DE29-4B1E-859A-0CB633B745B9 Q35771783-DFE0492E-D3CB-4DA7-AA75-813E743F928F Q35895174-946FF8EF-4FE7-4D34-A70A-EAE0F13747CF Q35929346-02471813-C8BF-48DA-87FE-821C53BA29BE Q36339461-EE20CF29-A73A-480E-8975-34144C5FFF95 Q36424068-9190FF99-50D6-40D1-82C8-5B3D7AA657A8 Q36427409-CB2D4DD7-D2E4-4CC5-BCD8-F988F3DC57DF Q36427538-D26AD85C-C44D-49CD-9595-5A0A9BF53F61 Q36618214-8AF97543-B7B3-4BE7-93AD-252D73A19C3D Q36785126-24952D70-D12C-4DEF-BB19-6DEA12DDF956 Q37035747-72E6FF94-7D76-49A7-8623-FC80DED0C974 Q37226521-D8F2ADA3-AB80-42C0-B8A0-BECEAC5A982E Q37407066-6AE2F693-FDA5-4CEB-BDC1-5237E0FEEA42 Q37409700-25AD359E-ED30-4715-99DB-F938A3556C2F Q37452768-18BD00E9-D534-46D2-8F74-7A0A14B44B5D Q37571743-2BBC5A06-B1B6-4584-927F-B612605AE39E Q37634294-97C62A8E-6981-4DFF-A53D-37E940EEE6BE Q38271116-88A43C56-CA5B-4B60-A5AB-17DA7B757B4D Q38615302-B6F7EB25-2D86-4ACA-86C3-1F145EB0C22C Q38706148-2E630132-E277-4B86-A8E1-8F5B17CAB936 Q38743138-F2DA1595-6784-48CD-9232-F1CBE1F6C290 Q38789124-D8F63D85-2E6E-406B-A766-300D5F5D4DCA Q38904605-8780289B-9817-4CA0-ADEE-5783752CEAE6 Q38955193-15D6173E-DA54-4592-B126-9A25DDFF8ED6

P2860

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

http://www.wikidata.org/entity/Q30413713

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Apparent diffusion coefficient ...... acizumab: a multi-center study

@ast

Apparent diffusion coefficient ...... acizumab: a multi-center study

@en

type

label

Apparent diffusion coefficient ...... acizumab: a multi-center study

@ast

Apparent diffusion coefficient ...... acizumab: a multi-center study

@en

prefLabel

Apparent diffusion coefficient ...... acizumab: a multi-center study

@ast

Apparent diffusion coefficient ...... acizumab: a multi-center study

@en

P1433

Q30413713-EB9A8F44-E3AB-4BA9-B5AD-DC83320753B9

P1476

Q30413713-1957DD51-C646-49BC-921E-BD6DB1F66352

P2093

Q30413713-02EA6F42-AA99-4E2A-A55F-A35DC91EB9CE

Q30413713-0BA08C20-D78E-4EE7-A73D-396B17788A9B

Q30413713-14D31CCA-09CC-4F9F-8D2B-2008D3499C9A

Q30413713-27BA16DF-22E5-42A6-BA21-C46223197394

Q30413713-37152754-5BB2-4337-B36D-2D4972CDA7C0

Q30413713-4436B7E3-1AB8-4549-AF44-19A92AE26B74

Q30413713-61BEC901-234A-4FAF-8963-17974549472F

Q30413713-6BE71547-263A-433E-9D1A-9A2167FC6AE3

Q30413713-77AAA4F6-CC4E-49A9-875A-217A0513167E

Q30413713-948D63F0-E729-42D3-9230-47F8F22498B0

P2860

Q30413713-016810FF-619B-426C-A8BF-4829054B16EE

Q30413713-0EC7D8E9-6BE8-46D4-8742-065C7895C94B

Q30413713-3270ED57-46D0-41D1-AD9C-F3A76825A685

Q30413713-3B0F813D-9F95-45FA-A61D-DC31BE76BD90

Q30413713-4BE32C61-5DBE-49BB-9F04-7ADBD2BD97CF

Q30413713-5BF9AAB9-E694-454A-B31B-CE8A9D5AAFD2

Q30413713-6384FEAD-1751-4421-BDD3-831227408FE2

Q30413713-69044325-E143-45AC-8BDE-549A100EDA6B

Q30413713-7C7B3D38-8F0B-405C-8B2E-B57E5EEA63D8

Q30413713-8219840C-90F1-4268-BD44-253A0D27A5D1

P2888

Q30413713-25C9B693-C08D-4290-99FB-8C9DE1C275CC

P304

Q30413713-791B3522-7574-453D-ACC6-2B088B58549F

P31

Q30413713-2E7622E6-F82E-4ABD-AA4C-DDACE602AD3F

P356

Q30413713-A24AC114-CC57-4FCC-A537-1D5DFEBE4BEC

P433

Q30413713-CA3FC0AD-A9E7-4838-8877-C709084B99A4

P478

Q30413713-4727263A-D565-4BE1-9540-B5742DC90001

P50

Q30413713-207798C7-E4E2-4C31-B593-5B81089BFE86

Q30413713-39BDF517-A9FB-44C6-89E0-71326AFB5EC0

P577

Q30413713-BC6DA2EA-04F1-4E53-B292-972002E6D70B

P6179

Q30413713-6E24DC2A-6901-46EC-899B-5544917CEFBD

P698

Q30413713-C6776525-FAD6-4A53-BB06-C1B70CD23601

P921

Q30413713-DEF7F2D8-9F43-4E12-9133-37C0C2A51598

Q30413713-E9B554BC-7DF7-4B23-AFB5-0886364657CF

P932

Q30413713-E6718F2D-166D-4100-93A1-CDBE92AE6C50

P356

S11060-012-0847-Y

P1433

Journal of Neuro-Oncology

P1476

Apparent diffusion coefficient ...... acizumab: a multi-center study

@en

P2093

Albert Lai

http://www.w3.org/2001/XMLSchema#string

Benjamin M Ellingson

http://www.w3.org/2001/XMLSchema#string

Dan Barboriak

http://www.w3.org/2001/XMLSchema#string

David Schiff

http://www.w3.org/2001/XMLSchema#string

Dawit Aregawi

http://www.w3.org/2001/XMLSchema#string

Geoffrey S Young

http://www.w3.org/2001/XMLSchema#string

Hyun J Kim

http://www.w3.org/2001/XMLSchema#string

James Vredenburgh

http://www.w3.org/2001/XMLSchema#string

Jing Wu

http://www.w3.org/2001/XMLSchema#string

Lauren E Abrey

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

Potential of diffusion imaging in brain tumors: a review.

Diffusion imaging: insight to cell status and cytoarchitecture.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Pseudoprogression and pseudoresponse in the treatment of gliomas.

Advances in MRI assessment of gliomas and response to anti-VEGF therapy.

P2888

s11060-012-0847-y

P304

491-498

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-012-0847-Y

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan Goldin

P577

2012-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1049462100

http://www.w3.org/2001/XMLSchema#string

P698

22426926

http://www.w3.org/2001/XMLSchema#string

P921

P932

3997502

http://www.w3.org/2001/XMLSchema#string